These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 30397066)
21. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651 [TBL] [Abstract][Full Text] [Related]
23. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients. Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. Dooley KE; Denti P; Martinson N; Cohn S; Mashabela F; Hoffmann J; Haas DW; Hull J; Msandiwa R; Castel S; Wiesner L; Chaisson RE; McIlleron H; J Infect Dis; 2015 Jan; 211(2):197-205. PubMed ID: 25081933 [TBL] [Abstract][Full Text] [Related]
25. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219 [TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111 [TBL] [Abstract][Full Text] [Related]
27. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658 [TBL] [Abstract][Full Text] [Related]
28. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Cohen K; Grant A; Dandara C; McIlleron H; Pemba L; Fielding K; Charalombous S; Churchyard G; Smith P; Maartens G Antivir Ther; 2009; 14(5):687-95. PubMed ID: 19704172 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558 [TBL] [Abstract][Full Text] [Related]
30. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Francis J; Mngqibisa R; McIlleron H; Kendall MA; Wu X; Dooley KE; Firnhaber C; Godfrey C; Cohn SE; Denti P; Clin Pharmacol Ther; 2021 Oct; 110(4):1057-1065. PubMed ID: 34151439 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV. Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669 [TBL] [Abstract][Full Text] [Related]
32. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure. Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children. Yang H; Enimil A; Gillani FS; Antwi S; Dompreh A; Ortsin A; Adu Awhireng E; Owusu M; Wiesner L; Peloquin CA; Kwara A Pediatr Infect Dis J; 2018 Jan; 37(1):43-51. PubMed ID: 28719501 [TBL] [Abstract][Full Text] [Related]
34. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study. Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961 [TBL] [Abstract][Full Text] [Related]
35. Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. Schaaf HS; Willemse M; Cilliers K; Labadarios D; Maritz JS; Hussey GD; McIlleron H; Smith P; Donald PR BMC Med; 2009 Apr; 7():19. PubMed ID: 19386087 [TBL] [Abstract][Full Text] [Related]
36. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. Sekaggya-Wiltshire C; Castelnuovo B; von Braun A; Musaazi J; Muller D; Buzibye A; Gutteck U; Henning L; Ledergerber B; Corti N; Lamorde M; Fehr J; Kambugu A BMJ Open; 2017 Sep; 7(9):e014679. PubMed ID: 28928173 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804 [TBL] [Abstract][Full Text] [Related]
39. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Kwara A; Ramachandran G; Swaminathan S Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):55-68. PubMed ID: 19968575 [TBL] [Abstract][Full Text] [Related]